Pre-exposure prophylaxis against HIV infection: Which drugs should be tested?

Giving anti-HIV drugs to HIV-negative people who are at high risk of HIV infection (pre-exposure prophylaxis or "PREP") may become an important tool in curbing the HIV pandemic, says a group of researchers in a policy paper in PLoS Medicine.

Inge Derdelinckx (University Medical Center, Utrecht) and colleagues formulate criteria for what would be the optimal drug to test as a PREP candidate in clinical trials. They then evaluate existing antiviral drugs to see which of these would best fit these criteria.

Based on their analysis, they conclude that lamivudine (3TC) would be a good PREP candidate to test, "given its relative safety, ease of use, mode of action and pharmacology, antiviral profile, and cost-effectiveness." Whether its use would be optimal as monotherapy or in combination with another antiviral, they say, is still unknown.

"Randomised clinical trials to evaluate 3TC's efficacy in preventing new HIV infections are the only way forward," say the authors.

###

* * * * * * * * EMBARGO: MONDAY, 6 November, 5 P.M. PDT * * * * * * * * *

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Citation: Derdelinckx I, Wainberg MA, Lange JMA, Hill A, Halima Y, et al. (2006) Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med 3(11): e454.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030454

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-boucher.pdf

CONTACT:
Charles Boucher
University Medical Center Utrecht
Eijkman Winkler Center
Department of Virology
Heidelberglaan 100
Utrecht 3584CX Netherlands
+31 302506526
+31 302505426 (fax)
c.boucher@umcutrecht.nl

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

Problems are not stop signs, they are guidelines.
~ Robert Schuller